Compare Ferrari NV (RACE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs TG Therapeutics Inc — how do they compare? Ferrari NV trades at $371.61 (market cap $65.25B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: Ferrari NV is far larger — about 7.9× TG Therapeutics Inc's market cap, and Ferrari NV pays a 1.14% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| RACE | TGTX | |
|---|---|---|
Market Cap | $65.25B | $8.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $517.65 | $59.06 |
52-Week Low | $314.63 | $26.39 |
Enterprise Value | $66.46B | $8.50B |
Dividend Yield | 1.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $369.97, down 1.82% today, with a bullish technical outlook supported by moving averages and key support at $370. The company demonstrates strong fundamentals with consistent earnings beats, a 22.19% net margin, and robust cash flow from operations of $2.35B in 2025. Recent news highlights ongoing share buybacks and the upcoming Q2 2026 earnings report on July 30.
The investment outlook remains positive given Ferrari's premium brand positioning, pricing power, and analyst consensus price target of $467.50 implying 26% upside. Risks include execution challenges with new EV models, economic sensitivity, and high valuation multiples. Wall Street sentiment is strongly bullish with 72% buy ratings.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
